BACKGROUND Liquid biopsies that are based on analysis of cell-free DNA from plasma
offer diagnostic information that is otherwise accessible conventionally through invasive …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Cell-free DNA (cfDNA) concentrations from patients with cancer are often elevated
compared with those of healthy controls, but the sources of this extra cfDNA have never …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

Cell-free DNA fragments are shed into the bloodstream by tumor cells. The analysis of
circulating tumor DNA (ctDNA), commonly known as liquid biopsy, can be exploited for a …

Plasma DNA fragmentomics is an emerging area of research covering plasma DNA sizes,
end points, and nucleosome footprints. In the present study, we found a significant increase …

Malignant tumors shed DNA into the circulation. The transient half-life of circulating tumor
DNA (ctDNA) may afford the opportunity to diagnose, monitor recurrence, and evaluate …

In kidney transplantation, the use of minimally invasive damage biomarkers that are more
sensitive and specific than plasma creatinine will be crucial to enable early, actionable …

Plasma consists of DNA released from multiple tissues within the body. Using genome-wide
bisulfite sequencing of plasma DNA and deconvolution of the sequencing data with …

Background The promise of precision cancer medicine presently centers around the
genomic sequence of a patient's tumor being translated into timely, actionable information to …